nach oben

Erschienen in:

01.06.2014 | Preclinical study

Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study

verfasst von: Mohammed A. Aleskandarany, Ola H. Negm, Andrew R. Green, Mohamed A. H. Ahmed, Christopher C. Nolan, Patrick J. Tighe, Ian O. Ellis, Emad A. Rakha

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Epithelial mesenchymal transition (EMT), as defined by loss of epithelial characteristics and gain of a mesenchymal phenotype, has been reported in vivo although the occurrence of events remains unclear. This study aims at exploration of EMT portraits of breast cancer (BC) with relevance to different molecular pathways, especially potential EMT triggers and BC molecular subtypes. Immunohistochemical (IHC) expression of markers/triggers of EMT was studied on a well-defined cohort of invasive non-lobular BC (n = 1,035), prepared as tissue microarrays. IHC panel of biomarkers included cadherins (cad; E-cad and N-cad), TGFβ1, PIK3CA, pAkt, and others. Reverse phase protein array (RPPA) was performed for quantitative analysis of proteins extracted from formalin fixed paraffin embedded tissues of a subset of cases from this cohort. Four combinatorial phenotypic groups representing cadherin switch were defined, including E-cad⁺/N-cad⁻, E-cad⁻/N-cad⁻, E-cad⁺/N-cad⁺, and E-cad⁻/N-cad⁺. Statistically significant association was noticed between these phenotypes and histological tumour grade, tumour type and size and NPI staging classes. The E-cad/N-cad switch occurred more frequently in the triple negative molecular class, both basal and non-basal, and in the HER2⁺ subtype than in luminal BC. Significant outcome differences were observed between cadherin switch combinatorial groups regarding BCSS and DMFS (p < 0.001). Results of RPPA confirm those observed using IHC regarding differential expressions of EMT markers/triggers. EMT/cadherin switch programs in BC appear to occur in synergy with TGFβ1 and PIK3/Akt pathways activation. These data explain, at translational proteomic level, the molecular heterogeneity and in turn the varied clinical behaviour of BC molecular subtypes. RPPA is a promising high-throughput technique in monitoring subtle quantitative changes in protein expression in archival material.

Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7(2):131–142PubMedCrossRef

Moustakas A, Heldin CH (2007) Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 98(10):1512–1520PubMedCrossRef

Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454PubMedCrossRef

Iwatsuki M et al (2010) Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 101(2):293–299PubMedCrossRef

Cardiff R (2010) The pathology of EMT in mouse mammary tumorigenesis. J Mammary Gland Biol Neoplasia 15(2):225–233PubMedCentralPubMedCrossRef

Tomaskovic-Crook E, Thompson EW, Thiery JP (2009) Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res 11(6):213PubMedCentralPubMedCrossRef

Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9(4):265–273PubMedCrossRef

Wu Y, Zhou BP (2008) New insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim Biophys Sin (Shanghai) 40(7):643–650CrossRef

Xue C et al (2003) The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res 63(12):3386–3394PubMed

10.

Giampieri S et al (2009) Localized and reversible TGF[beta] signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 11(11):1287–1296PubMedCentralPubMedCrossRef

11.

Tarin D (2005) The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 65(14):5996–6001PubMedCrossRef

12.

Wicki A et al (2006) Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9(4):261–272PubMedCrossRef

13.

Tse JC, Kalluri R (2007) Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 101(4):816–829PubMedCrossRef

14.

Wendt MK, Smith JA, Schiemann WP (2010) Transforming growth factor-beta-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 29(49):6485–6498PubMedCentralPubMedCrossRef

15.

Yang J et al (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117(7):927–939PubMedCrossRef

16.

Lamouille S, Derynck R (2011) Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-beta-induced epithelial-mesenchymal transition. Cells Tissues Organs 193(1–2):8–22PubMedCrossRef

17.

Albasri A et al (2009) C-terminal Tensin-like (CTEN) is an oncogene which alters cell motility possibly through repression of E-cadherin in colorectal cancer. J Pathol 218(1):57–65PubMedCrossRef

18.

Peinado H, Portillo F, Cano A (2004) Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 48(5–6):365–375PubMedCrossRef

19.

Hazan RB et al (2004) Cadherin switch in tumor progression. Ann N Y Acad Sci 1014:155–163PubMedCrossRef

20.

Ahmed N, Thompson EW, Quinn MA (2007) Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J Cell Physiol 213(3):581–588PubMedCrossRef

21.

Josson S et al (2010) Tumor-stromal interactions influence radiation sensitivity in epithelial-versus mesenchymal-like prostate cancer cells. J Oncol. doi:10.1155/2010/232831 PubMedCentralPubMed

22.

Lin K et al (2010) The role of B-RAF mutations in melanoma and the induction of EMT via dysregulation of the NF-kappaB/Snail/RKIP/PTEN circuit. Genes Cancer 1(5):409–420PubMedCentralPubMedCrossRef

23.

Sarrio D et al (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68(4):989–997PubMedCrossRef

24.

Spurrier B, Ramalingam S, Nishizuka S (2008) Reverse-phase protein lysate microarrays for cell signaling analysis. Nat Protoc 3(11):1796–1808PubMedCrossRef

25.

Speer R et al (2007) Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy. Cancer Genomics Proteomics 4(3):157–164PubMed

26.

Brase JC et al (2010) Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification. Proteome Sci 8:36PubMedCentralPubMedCrossRef

27.

Abd El-Rehim DM et al (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116(3):340–350PubMedCrossRef

28.

Rakha EA et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15(7):2302–2310PubMedCrossRef

29.

Aleskandarany MA et al (2010) Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer. Int J Cancer 126(7):1761–1769PubMed

30.

Sasaki K et al (2009) Significance of twist expression and its association with E-cadherin in esophageal squamous cell carcinoma. J Exp Clin Cancer Res 28:158PubMedCentralPubMedCrossRef

31.

Bryan RT, Tselepis C (2010) Cadherin switching and bladder cancer. J Urol 184(2):423–431

32.

Yilmaz M, Christofori G (2010) Mechanisms of motility in metastasizing cells. Mol Cancer Res 8(5):629–642

33.

McCarty KS Jr et al (1985) Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109(8):716–721PubMed

34.

Nirmalan NJ et al (2009) Development and validation of a novel protein extraction methodology for quantitation of protein expression in formalin-fixed paraffin-embedded tissues using western blotting. J Pathol 217(4):497–506PubMedCrossRef

35.

Cheang MC et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5):1368–1376PubMedCrossRef

36.

Nguyen DX, Massague J (2007) Genetic determinants of cancer metastasis. Nat Rev Genet 8(5):341–352PubMedCrossRef

37.

Yoder BJ, Wilkinson EJ, Massoll NA (2007) Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast. Breast J 13(2):172–179PubMedCrossRef

38.

Ellis IO et al (2005) Pathology reporting of breast disease : a joint document incorporating the third edition of the NHS Breast Screening Programme’s Guidelines for pathology reporting in breast cancer screening and the second edition of the Royal College of Pathologists’ minimum dataset for breast cancer histopathology. In: NHS Cancer Screening Programmes, Royal College of Pathologists, London

39.

Marginean F et al (2010) Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast. Mod Pathol 23(10):1357–1363PubMedCrossRef

40.

Aleskandarany M et al (2010) Epithelial mesenchymal transition in invasive breast carcinoma: molecular pathways and relation to molecular subtypes. J Pathol 222(S1):S1–S51CrossRef

41.

Mahler-Araujo B et al (2008) Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype. J Clin Pathol 61(5):615–620PubMedCrossRef

Titel: Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study
verfasst von: Mohammed A. Aleskandarany
Ola H. Negm
Andrew R. Green
Mohamed A. H. Ahmed
Christopher C. Nolan
Patrick J. Tighe
Ian O. Ellis
Emad A. Rakha
Publikationsdatum: 01.06.2014
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2014
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-014-2927-5

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Re-attendance at biennial screening mammography following a repeated false positive recall

Birth size in the most recent pregnancy and maternal mortality in premenopausal breast cancer by tumor characteristics

Folate intake and the risk of breast cancer: a systematic review and meta-analysis

Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study

Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry

Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie